Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat-to-target versus routine care ustekinumab maintenance in Crohn's disease
NL-OMON47710Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ustekinumab in Crohn's disease (2 arms), sponsored by Janssen Pharmaceutical. Started Aug 2017; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON47710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47710.